+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2024

  • ID: 4668466
  • Drug Pipelines
  • November 2018
  • Region: Global
  • 400 Pages
  • Kuick Research

FEATURED COMPANIES

  • Autolus
  • Bluebird
  • Cellectis
  • Eureka Therapeutics
  • Immune Therapeutics
  • Kite Pharma

The research in immunotherapy has unlocked the way to harness an individual’s immune response to fight against the tumors and cancers. Many of the ideas have tried to make the use of natural killer cells or B cell, however, the research has not moved a past conceptual thinking. Immuno-oncology is an evolving treatment modality with the agents which were studied for their potential to provide the long-term survival across a broad range of tumor types.

It is important to determine the advancement in this field and the use of new immunotherapies to achieve the best patient outcomes. The area of investigation is broad and includes the combining or sequencing the immunotherapies which target the immune pathways and sequencing an immunotherapeutic agent. CD-19 redirected chimeric antigen receptor is one of the immunotherapeutic modality which has been recently demonstrated the efficiency in re-inducing the remission in patients with multiple relapse B-acute lymphoblastic leukemia.

The global CAR-T cell therapy market boasts of a robust clinical pipeline under development with more than 200 products under various stages of development. As of 2018, only two products - Yescarta by Gilead Science and Kymriah by Novartis have made it into the market. Both the products have been approved by the FDA for the treatment of acute lymphoblastic leukemia (ALL), a rare type of blood cancer.

The global CAR-T cell therapy market is dominated by the US due to its early entry into the segment followed by the European Union. However, owing to the growing prevalence of Blood cancer in Europe, the CAR-T cell market might become a burgeoning market in the region during the forecast period. The global CAR-T cell market is bound to grow leaps and bound with a staggering CAGR of 40%, crossing the US$ 700 Million mark by 2024 driven by better market penetration, affordability, and accessibility.

This report on the ‘global CAR-T cell Therapy market’ is a result of an intensive study of the novel segment and its future market potential. The report has been made with a key focus on the current market trends, CAR-T cell products and their superiority to traditional cancer therapy methods. The report also provides key insights into the market performance of existing CAR-T cell products, recent developments and market dynamics that might impact its future.  The report concludes with effective forecast data and future projections which clearly highlights it as one of the most promising markets in the modern cancer therapy segment.

Report Highlights

  • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action
  • Sales Analysis of CAR - T Cell Therapy
  • CAR - T Cell Therapy Market Opportunity:  US$ 700 Million
  • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase:  236 Therapies
  • CAR-T Cell Therapies in Highest Phase:  Preclinical
  • Marketed  CAR-T Cell Therapies: 2 ( Yescarta & Kymriah)
  • Global Market Scenario of CAR T Cell Therapy
  • Global CAR T Cell Therapy Market Future Prospects
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Autolus
  • Bluebird
  • Cellectis
  • Eureka Therapeutics
  • Immune Therapeutics
  • Kite Pharma

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology
1.1 Overview
1.2 History & Development of CAR-T Technology

2. Development of Chimeric Antigen Receptor (CAR) T-Cell Design
2.1 Structure of CAR-T Cell
2.2 1st Generation Chimeric Antigen Receptor
2.3 2nd & 3nd Generation CAR-T Cell

3. Chimeric Antigen Receptor Design Standards
3.1 CAR Modified T-Cells: Targeting
3.2 CAR Modified T-Cell: Signaling

4. CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action
4.1 Process of CAR T-Cell Therapy
4.2 Mechanism of Action

5. Approaches to Improve the Efficacy of CAR-T Cell Therapy
5.1 Introduction
5.2 Targeting the Tumor Stroma with CAR-T Cells
5.3 Targeting the Cytokine Networks
5.4 Combination Strategies for CAR-T Cells
5.5 Targeting the Immune Checkpoints

6. Global CAR T-Cell Therapy - Clinical Trials for Cancer Treatment
6.1 Acute Lymphoblastic Leukemia
6.2 Multiple Myeloma
6.3 Brain Tumors
6.4 Lymphoma
6.5 Solid Tumors

7. CAR-T Cell Therapy Market Analysis by Product
7.1 Kymriah by Novartis
7.2 Yescarta by Gilead

8. Recent Advances Impacting the CAR - T Cell Market

9. Sales Analyis of CAR - T Cell Therapy

10. Cost Analysis & Market Potential of CAR - T Cell Therapy
10.1 Manufacturing Cost Analysis of CAR-T Cell Therapy Products
10.2 Price Analysis of CAR-T Cell Therapy
10.3 Global - Estimated Potential Customer Base & Revenue Analysis

11. Global CAR T-Cell Therapy Market Overview
11.1 Market Share of Cancer Immunotherapy by Technique
11.2 CAR-T Cell Therapy Market Value

12. Global CAR-T Cell Therapy Market Dynamics
12.1 Favorable Parameters
12.2 Challenges

13. Global CAR-T Cell Therapy Market Future Outlook

14. Global CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Clinical
14.4 Phase-I
14.5 Phase-I/II
14.6 Phase-II

15. Marketed CAR-T Cell Therapies Clinical Insight
15.1 Axicabtagene Ciloleucel (Yescarta)
15.2 Tisagenlecleucel (Kymriah)

16. Competitive Landscape
16.1 Autolus
16.2 Bellicum
16.3 Bluebird
16.4 Celgene
16.5 Cellectis
16.6 Celyad
16.7 Eureka Therapeutics
16.8 Fortress Biotech
16.9 Immune Therapeutics
16.10 Juno Therapeutics
16.11 Kite Pharma
16.12 Novartis
16.13 Sorrento therapeutics
16.14 TILT Biotherapeutics
16.15 Ziopharm

List of Figures
Figure 1-1: Historical Development of CAR-T Cell Therapy
Figure 2-1: Structure of Chimeric Antigen Receptor
Figure 2-2: First Generation Chimeric Antigen Receptor
Figure 2-3: Second Generation Chimeric Antigen Receptor
Figure 2-4: Third Generation Chimeric Antigen Receptor
Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T-Cell
Figure 4-1: Delivery Pipeline of CAR-T Cell Therapy Process
Figure 4-2: CAR T Cell Therapy Mechanism of Action
Figure 5-1: Strategies to Improve CAR T Cell Therapy
Figure 6-1: CAR T Cell Therapy in Brain Tumors
Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma
Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor
Figure 7-1: Kymriah - Product Overview
Figure 7-2: Yescarta - Product Overview
Figure 9-1: US – Total Lymphoblastic Leukemia Patients & Kymriah Eligible Patients(%), 2018
Figure 9-2: Global - Kymriah Sales (US$ Million), 2018
Figure 10-1: Adoptive T-Cell Therapy Clinical Trials to Investigate the Efficacy & Safety (%), 2018
Figure 10-2: CAR-T cell - Estimated Manufacturing Cost (US$), 2018
Figure 10-3: Price Analysis – CAR-T Cell Therapy (US$/Patient), 2018
Figure 10-4: US - Distribution of CMS & out of Pocket Cost in CAR T Cell (US$/patient), 2018
Figure 10-5: Yescarta – Complete Cost Analyis for CAR T-Cell Treatment (US$), 2018
Figure 10-6: US - Incidence of Acute Lyphocytic Leukemia (‘000’), 2018
Figure 10-7: US - Estimated Patient Base for CAR T cell Therapy (Number), 2018
Figure 10-8: US – Current Market Revenue v/s Total Potential Revenue of CAR T cell Therapy (US$), 2018
Figure 10-9: Europe - Total Eligible Patients v/s Patients Receiving CART T Cell Treatment (Number), 2018
Figure 11-1: Cancer Immunotherapy - Market Size of CAR T Cell by Technique (%), 2018
Figure 12-1: Favorable Market Parameters of CAR T Cell Therapy
Figure 12-2: Challenges to Market Growth of CAR T Cell Therapy
Figure 13-1: Global - Cancer Immunotherapeutic Market Forecast (US$ Billion), 2018-2024
Figure 13-2: Future Potential Immuno-Oncology
Figure 13-3: Global - CAR T Cell Therapy Market Opportunity (US$ Million), 2018 -2024
Figure 14-1: Global - CAR-T Cell Therapies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 14-2: Global - CAR-T Cell Therapies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 14-3: Global – Discontinued CAR-T Cell Therapies Clinical Pipeline by Phase (%),2018 till 2024
Figure 14-4: Global - Discontinued CAR-T Cell Therapies Clinical Pipeline by Phase (Number), 2018 till 2024

List of Tables
Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
Table 16-1: Clinical Pipelines of Products

Note: Product cover images may vary from those shown
  • Autolus
  • Bellicum
  • Bluebird
  • Celgene
  • Cellectis
  • Celyad
  • Eureka Therapeutics
  • Fortress Biotech
  • Immune Therapeutics
  • Juno Therapeutics
  • Kite Pharma
  • Novartis
  • Sorrento therapeutics
  • TILT Biotherapeutics
  • Ziopharm
Note: Product cover images may vary from those shown
Adroll
adroll